GW610742

GW610742 Powder

 

Product Name: GW 0742

Alias: GW 610742, GW-0742

CAS: 317318-84-6

MF: C21H17F4NO3S2

Purity: 99.50%

Dosage: 20-30mg per day

Grade: Pharmaceutical Grade

Appearance: White powder

Packing Methods: designed disguised packing ways, 100% pass custom guarantee

Payment: T/T, Western Union,Money Gram, Bitcoin

Usage: GW 0742 had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease.

GW0742, also known as GW610742, is a PPAR agonist. GW0742 Induces Early Neuronal Maturation of Cortical Post-Mitotic Neurons. GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. GW0742 has direct protective effects on right heart hypertrophy. GW0742 may enhance lipid metabolism in heart both in vivo and in vitro.

GW 0742 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation.

GW0742 has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in human.

Increase in endurance

Increase in stamina

Decreases bad cholesterol (LDL)

Increases good cholesterol (HDL)

Burns fat

Reduces inflammation

Uses:

GW0742 is a small molecule agonist of the human Peroxisome Proliferator-Activated Recept δ (PPAR δ). It shows an EC50 of 1.1 nM against PPAR δ with 100-fold selectivity over the other human subtypes.

The highest antagonist activity for GW0742 was found for VDR and the androgen receptor (AR). Surprisingly, GW0742 behaved as PPAR agonist/antagonist activating transcription at lower concentration and inhibiting this effect at higher concentrations. A unique spectroscopic property of GW0742 was identified as well. In the presence of rhodamine-derived molecules, GW0742+ increased fluorescence intensity and fluorescence polarization at an excitation wavelength of 595 nm and emission wavelength of 615 nm in a dose dependent manner.

The GW0742-inhibited NR-coactivator binding resulted in a reduced expression of five different NR target genes in LNCaP cells in the presence of agonist. Especially VDR target genes CYP24A1, IGFBP-3 and TRPV6 were negatively regulated by GW0742. GW0742 is the first VDR ligand inhibitor lacking the secosteroid structure of VDR ligand antagonists. Nevertheless, the VDR-meditated downstream process of cell differentiation was antagonized by GW0742 in HL-60 cells that were pretreated with the endogenous VDR agonist 1,25-dihydroxyvitamin D3.

Hot Tags: gw610742, China gw610742 manufacturers, suppliers, factory, Boldenone Cypionate, Clomiphene Citrate Raw Powder, Prohormone, Phenylpiracetam Hydrazide, IGF-DES, Fareston